Obesity Clinical Trials in Dallas, Texas

25 studies are recruiting for obesity in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

   The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Fortrea Clinical Research Unit - Dallas, Dallas, Texas

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT07908316 on ClinicalTrials.gov

2. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Cedar Health Research, LLC, Dallas, Texas

   Locations

   686 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

3. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Velocity Clinical Research - Dallas /ID# 282734, Dallas, Texas

   Locations

   64 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

4. The RESET System Pivotal Clinical Trial (Protocol Revision K)

   A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and eff…

   Stage

   Not phased

   Ages

   22 to 65

   Site

   M3 Wake Research, Dallas, Texas

   Locations

   27 in total

   Run by

   Morphic Medical Inc.

   See if you can join NCT04101669 on ClinicalTrials.gov

5. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Velocity Clinical Research, Dallas, Dallas, Texas

   Locations

   143 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

6. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   FutureSearch Trials of Dallas, Dallas, Texas

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

7. A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

   The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), …

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Fortrea Clinical Research Unit, Dallas, Texas

   Locations

   2 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07808060 on ClinicalTrials.gov

8. A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

   The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participa…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Fortrea Clinical Research Unit, Dallas, Texas

   Locations

   3 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07808073 on ClinicalTrials.gov

9. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Velocity Clinical Research, Dallas, Dallas, Texas

   Locations

   57 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

10. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Cedar Health Research, LLC, Dallas, Texas

    Locations

    92 in total

    Run by

    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

11. Spinal Cord Injury Model Systems (SCIMS) - Education Module

    The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Baylor Scott & White Institute for Research, Dallas, Texas

    Locations

    3 in total

    Run by

    University of Miami

    See if you can join NCT06003686 on ClinicalTrials.gov

12. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UT Southwestern Med Center, Dallas, Texas

    Locations

    74 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07533175 on ClinicalTrials.gov

13. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Velocity Clin Res, Dallas, Dallas, Texas

    Locations

    303 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07564414 on ClinicalTrials.gov

14. A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UT Southwestern Med Center, Dallas, Texas

    Locations

    45 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07668414 on ClinicalTrials.gov

15. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (trea…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    North Texas Endocrine Center, Dallas, Texas

    Locations

    41 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07720271 on ClinicalTrials.gov

16. AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Velocity Clinical Res-Dallas, Dallas, Texas

    Locations

    72 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07339423 on ClinicalTrials.gov

17. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Velocity Clinical Research, Dallas, Dallas, Texas

    Locations

    158 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07321886 on ClinicalTrials.gov

18. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Locations

    185 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07392190 on ClinicalTrials.gov

19. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Cedar Health Research, Dallas, Texas

    Locations

    62 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07770841 on ClinicalTrials.gov

20. Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

    The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic ner…

    Stage

    EARLY_Phase 1

    Ages

    18 to 55

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04838678 on ClinicalTrials.gov

21. Effects of Obesity in the Aged

    The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigat…

    Stage

    Not phased

    Ages

    65 to 75

    Site

    Institute for Exercise and Environmental Medicine, UT Southwestern and Texas Health Resources, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05028309 on ClinicalTrials.gov

22. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

    Stage

    Phase 2

    Ages

    7 to 25

    Site

    University of Texas, Southwestern, Dallas, Texas

    Locations

    16 in total

    Run by

    Etan Orgel

    See if you can join NCT05082519 on ClinicalTrials.gov

23. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Renal Disease Research Institute, Dallas, Texas

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

24. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mercy Family Clinic, Dallas, Texas

    Locations

    81 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07509307 on ClinicalTrials.gov

25. Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

    The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contrib…

    Stage

    Not phased

    Ages

    55 to 90

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05723679 on ClinicalTrials.gov